Biopolym. Cell. 2001; 17(5):434-440.
http://dx.doi.org/10.7124/bc.0005D1
Molecular Biomedicine
Correlation of HLA-DR antigens, level of immunogenetic indexes and morphologic changes of the thymus gland at myasthenia
1Klimova E. M.
  1. Kharkov Institute of General and Emergency Surgery AMS of Ukraine
    Balakirev, 1, Kharkov, Ukraine, 61018

Abstract

The key risk factors inducing the changes of thymus gland at myasthenia are different and their role is not studied completely. A possible correlation of isoantigen phenotypes HLA-DR with the character of ultrastructural pathology of thymus gland and the changes of immunoreactivity at myasthenia has been studied in this work. 70 % correlation with HLA-DR5 at the hyperplasia of thymus gland has been revealed. In patients with tumoral lesion of mediastinum the reliable increasing of IgE and IL-4 levels has been observed in 87.S % cases. A high level of correlation with isoantigen HLA-DR7 (66 %) has been revealed at thymomas.
Full text: (PDF, in Russian)

References

[1] Balasa B, Deng C, Lee J, Bradley LM, Dalton DK, Christadoss P, Sarvetnick N. Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. J Exp Med. 1997;186(3):385-91.
[2] Kuzin MI, Geht BM. Myasthenia. M.: Meidtsina, 1996; 221 p.
[3] Kharchenko VP, Sarkisov DS, Vetshev PS, Zarat'yants VA. Diseases of thymus. M.: Triada-X, 1998.
[4] Rao VP, Balasa B, Carayanniotis G. Mapping of thyroglobulin epitopes: presentation of a 9mer pathogenic peptide by different mouse MHC class II isotypes. Immunogenetics. 1994;40(5):352-9.
[5] Kaul R, Shenoy M, Goluszko E, Christadoss P. Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis. J Immunol. 1994;152(6):3152-7.
[6] Bonini S, Rasi G, Matficardl P. Infection and allergy. Int J Imraunorehabilit. 2001; 3(2): 35-42.
[7] Lisak RP, Barchi RL. Myasthenia. Transl from English. M.: Meditsina, 1984. 270 p.
[8] Almon RR, Andrew CG, Appel SH. Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors. Science. 1974;186(4158):55-7.
[9] Sela M. Specific vaccines against autoimmune diseases. C R Acad Sci III. 1999;322(11):933-8.
[10] Pinching AJ. Diseases of the neuromuscular junction: pathophysiological mechanisms of myasthenia gravis and Eaton-Lambert syndrome. Neurotransmitter systems. En NH Legga. M.: Meditsina, 1982: 26-38.
[11] Yarilin AA. Apoptosis and its place in the immune processes. Immunologiiya. 1996; (6): 10-22.
[12] Shevniuk MM, Krivitski? DI, Fedotov AF, Sil'chenko VP, Bobrik II. [Clinico-morphologic analysis of thymus tumors in patients with myasthenia]. Vrach Delo. 1988;(8):75-7.
[13] Yarlin AA, Grinevitch YuA. Thymic structure and T-lymphocytes differentiation. K.: Naukova Dumka, 1991; 211 p.
[14] Za?rat'iants OV, Vetshev PS, Popova IV, Ippolitov IKh, Voronov LI. [Cortical-cell thymomas with predominance of so-called nurse-cells in patients with myasthenia]. Arkh Patol. 1991;53(1):15-20.
[15] Askarov SHA, Pinskaya LB, Turgunov AB. Genetic aspects of myasthenia. Med Zh Uzbekistana. 1989;5):62-4.
[16] Kirchner T, Schalke B, Melms A, von K?gelgen T, M?ller-Hermelink HK. Immunohistological patterns of non-neoplastic changes in the thymus in Myasthenia gravis. Virchows Arch B Cell Pathol Incl Mol Pathol. 1986;52(3):237-57.
[17] Konstantinova NA. Guidelines USSR Ministry of Health. M., 1986; 14 p.
[18] Lmanskaya OYu, Limanskiy AN. Polymerase chain reaction with modified primers. Ul'trazvukovaya diagnostika. 1995; (6-7):71-7.